Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

Katrina Wilcox Hagberg1 Boston Collaborative Drug Surveillance Program, Lexington, MA02421, USA

https://orcid.org/0000-0002-2407-2995

Rebecca Persson1 Boston Collaborative Drug Surveillance Program, Lexington, MA02421, USA

Catherine Vasilakis-Scaramozza1 Boston Collaborative Drug Surveillance Program, Lexington, MA02421, USA

Steve Niemcryk2 Celgene Corporation, Summit, NJ07901, USA

Michael Peng2 Celgene Corporation, Summit, NJ07901, USA

Maria Paris2 Celgene Corporation, Summit, NJ07901, USA

Anders Lindholm2 Celgene Corporation, Summit, NJ07901, USA

Susan Jick1 Boston Collaborative Drug Surveillance Program, Lexington, MA02421, USA;3 Boston University School of Public Health, Lexington, MA02421, USACorrespondence[email protected]

https://orcid.org/0000-0002-2215-1067

show all

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

Table 1 Characteristics of Study Population at Cohort Entry Date by Exposure

Table 2 Characteristics of Cases at the Index Date

Table 3 Incidence Rates (IR) and Incidence Rate Ratios (IRR) for Treated Herpes Zoster by Exposure in Patients with Psoriasis or PsA

Table 4 Incidence Rates (IR) for Treated Hepatitis C by Exposure in Patients with Psoriasis or PsA

Table 5 Incidence Rates (IR) for Treated Tuberculosis by Exposure in Patients with Psoriasis or PsA

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Herpes Zoster, Hepatitis C, and Tuberculosis Risk with Apremilast Compared to Biologics, DMARDs and Corticosteroids to Treat Psoriasis and Psoriatic Arthritis

Figures & data

Table 1 Characteristics of Study Population at Cohort Entry Date by Exposure

Table 2 Characteristics of Cases at the Index Date

Table 3 Incidence Rates (IR) and Incidence Rate Ratios (IRR) for Treated Herpes Zoster by Exposure in Patients with Psoriasis or PsA

Table 4 Incidence Rates (IR) for Treated Hepatitis C by Exposure in Patients with Psoriasis or PsA

Table 5 Incidence Rates (IR) for Treated Tuberculosis by Exposure in Patients with Psoriasis or PsA

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date